Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

New study to understand the association of winter "cold-air pools" with poor air quality

At times this winter, the greater Salt Lake City area has harbored the most polluted air in the United States. Now, researchers from the University of Utah and other institutions are starting a three-year, $1.3 million study to better understand the winter weather "inversion" conditions frequently associated with poor air quality.

3 Feb 2010

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion - development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and many patients suffer from significant breathlessness and distress. One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion.

3 Feb 2010

Hundred millions for biotech-licence

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).

3 Feb 2010

New device to eliminate pathogenic bacteria and viruses

A revolutionary new device is being launched today with the technology to eradicate 99.9999% of pathogenic airborne and surface bacteria and viruses.

3 Feb 2010

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates.

3 Feb 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

Hovione announces filing of new drug application in Japan for the influenza drug CS-8958

Hovione is announcing the filing of a new drug application in Japan by its licensee Daiichi Sankyo Company Ltd. for the influenza drug CS-8958, which is delivered using Hovione's TwinCaps(R) inhaler.

2 Feb 2010

CTS: More people are being admitted to Canadian hospitals each year with COPD

A review of Canadian data by the nation's leading lung specialists has provided the factual evidence to support what respirologists across the country have been suspecting for some time. Shockingly, more people are being admitted to Canadian hospitals each year with chronic obstructive pulmonary disease (COPD) than any other major chronic illness (including heart attacks) and that number has been increasing dramatically in recent years.

2 Feb 2010

Leapfrog Group urges hospitals to report infection rates for consumers’ benefit

For the first time, in 2009, The Leapfrog Group asked hospitals across the country on behalf of Leapfrog's purchaser members to publicly report their rates of one of the most common and deadly forms of hospital-acquired infections: central-line associated blood stream infections, or CLABSIs.

2 Feb 2010

Pandemic H1N1 influenza of swine origin has distinct means of transmission from seasonal flu

Current research suggests that pandemic H1N1 influenza of swine origin has distinct means of transmission from the seasonal flu, yet does not result in the pathogenic severity of avian flu viruses.

2 Feb 2010

Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C

The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats.

2 Feb 2010

Some states mull requiring prescription for meth ingredients

"State and local efforts to thwart methamphetamine production by further limiting consumer access to a popular decongestant are pitting law enforcement against pharmacists and patients," USA Today reports.

2 Feb 2010

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

Response Biomedical continues global market expansion, signs Guangzhou Wondfo Biotech in China

Response Biomedical Corporation announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company’s diagnostic products, expanding its strategic presence in this important global market.

2 Feb 2010

Researchers identify antiviral small molecule that is effective against numerous viruses

Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging.

2 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Whole grain intake prevents diabetes, heart diseases, and excess weight gain

Three daily servings of whole grains are recommended for prevention of type 2 diabetes, coronary heart disease, and excess weight gain. Yet few adolescents or young adults follow these guidelines, according to national survey data. In a study published in the February 2010 issue of the Journal of the American Dietetic Association, researchers from the School of Public Health, University of Minnesota report that young people are consuming less than 1 serving of whole grains per day. The study took an in-depth look at influencers, modifiable factors, and interventions that are critical for successfully addressing this gap.

1 Feb 2010

Consumers oppose prescription mandate; prefer alternative method to fight meth

Mississippians are expressing outrage at lawmakers' rush to change over-the-counter cold and allergy medicines containing pseudoephedrine (PSE) to a prescription (Rx) drug.

31 Jan 2010

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert Dr. Thomas Cherian will be honored by a group of the world’s leading infectious disease experts today for his pivotal work to accelerate access to vaccines preventing pneumococcal disease, the world’s leading vaccine-preventable killer of children under age five.

31 Jan 2010

Study identifies key demographic and psychological factors that predict protective behaviour during pandemics

A study that looked at how people behave during pandemics has identified key demographic and psychological factors that may predict protective behaviours. The study is published online today, 30th January 2010, in the British Journal of Health Psychology.

30 Jan 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

New study to understand the association of winter "cold-air pools" with poor air quality

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

Hundred millions for biotech-licence

New device to eliminate pathogenic bacteria and viruses

NanoBio awarded sixth U.S. patent covering its novel nanoemulsion technology

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Hovione announces filing of new drug application in Japan for the influenza drug CS-8958

CTS: More people are being admitted to Canadian hospitals each year with COPD

Leapfrog Group urges hospitals to report infection rates for consumers’ benefit

Pandemic H1N1 influenza of swine origin has distinct means of transmission from seasonal flu

Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C

Some states mull requiring prescription for meth ingredients

FDA and PATH collaborate to advance pneumococcal vaccine development for children

Response Biomedical continues global market expansion, signs Guangzhou Wondfo Biotech in China

Researchers identify antiviral small molecule that is effective against numerous viruses

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Whole grain intake prevents diabetes, heart diseases, and excess weight gain

Consumers oppose prescription mandate; prefer alternative method to fight meth

WHO pneumonia expert honored with PACE Global Leadership Award

Study identifies key demographic and psychological factors that predict protective behaviour during pandemics

Innovation in neuroscience drug discovery - eBook eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Innovation in neuroscience drug discovery - eBook eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in